Bumper crop of new drugs fails to lift big pharma R&D returns
Projected returns at 12 top drugmakers falls to an 8-year low of only 3.2%: Deloitte
Fri, Dec 15, 2017 - 5:50 AM
London
SO FAR this year, the US Food and Drug Administration, gatekeeper to the world's biggest drugs market, has approved 41 novel drugs compared with 22 for the whole of 2016.
It is shaping up to be a bumper year for drug approvals, with US officials clearing twice as many novel...
Register to read this article. Log in if you are already a subscriber.Register to read this article. Log in if you are already a subscriber.Please log in or subscribe to continue reading.
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes